resiquimod has been researched along with Lymphoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheadle, EJ; Dovedi, SJ; Fagnano, E; Honeychurch, J; Illidge, TM; Klein, C; Lipowska-Bhalla, G | 1 |
| Adlard, AL; Dovedi, SJ; Honeychurch, J; Illidge, TM; Melis, MH; Stratford, IJ; Wilkinson, RW | 1 |
| Greaves, P; Gribben, JG | 1 |
3 other study(ies) available for resiquimod and Lymphoma
| Article | Year |
|---|---|
A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; CD4-Positive T-Lymphocytes; Disease Models, Animal; Humans; Imidazoles; Killer Cells, Natural; Lymphocyte Activation; Lymphoma; Mice; Mice, Inbred C57BL; Rituximab; Toll-Like Receptor 7 | 2017 |
Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Disease Models, Animal; Imidazoles; Lymphocyte Activation; Lymphoma; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; T-Lymphocytes, Cytotoxic; Toll-Like Receptor 7 | 2013 |
A shot in the arm for radiotherapy.
Topics: Animals; Antineoplastic Agents; Imidazoles; Lymphoma; Membrane Glycoproteins; Toll-Like Receptor 7 | 2013 |